New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Abivax SA American Depositary Shares
ABVX
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

602M

Biotechnology

Next Earning date - 07 Nov 2024

602M

Biotechnology

Next Earning date - 07 Nov 2024

9.52USD
Shape0.55 ( 6.13%)
favorite-chart

Relative Strenght

favorite-chart

Volume Buzz

-38%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

44%
OverviewChart

Quote Panel

Shape
Updated October 12, 2024
1W -0.21 % 1M -18.52 % 3M -30.55 % 1Y 15.06 %

Key Metrics

Shape

  • Market Cap

    602.46M

  • Shares Outstanding

    63.28M

  • Share in Float

    55.03M

  • Dividende

    0

  • Earning Date

    07 Nov 2024

  • Price Target

    9.52

  • Average Volume

    90448

  • Beta

    1.452

  • Range

    7.995-17.02

  • Industry

    Biotechnology

  • Website

    https://www.abivax.com

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

0.00x

P/S Ratio

2.14x

P/B Ratio

0.3

Debt/Equity

0.0%

Net Margin

$-3.8

EPS

How ABVX compares to sector?

P/E Ratio

ABVX

-3x

Relative Strength

Shape

ABVX

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$7M

Shape-9%

2025-Revenue

$2.68

Shape-1%

2025-EPS

$7M

Shape9%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Laidlaw

initialise

Previous: Not converted

2024-07-29

Now: Buy

BTIG

initialise

Previous: Not converted

2024-05-20

Now: Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.21

arrow
arrow

N/A

-1.34
vs -1.42

Q4.21

arrow
arrow

N/A

-1.68
vs -1.90

Q2.22

arrow
arrow

N/A

-1.84
vs -1.34

Q4.22

arrow
arrow

N/A

-1.95
vs -1.68

Q2.23

arrow
arrow

N/A

-1.58
vs -1.84

Q4.23

arrow
arrow

N/A

-2.18
vs -1.95

Q1.24

arrow
arrow

N/A

1.45
vs NA

Q2.24

arrow
arrow

N/A

-0.74
vs -1.58

Sales GrowthShape

status-upYoY

Current

Estimates

Q2.21

arrow
arrow

NA

NA  vs NA

Q4.21

arrow
arrow

NA

NA  vs NA

Q2.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

1.1M  vs NA

Return on EquityShape

status-upQoQ

Q2.20

arrow
arrow

-161%

-1.61
vs -0.89

Q4.20

arrow
arrow

-124%

-1.24
vs -1.61

Q2.21

arrow
arrow

-696%

-6.96
vs -1.24

Q4.21

arrow
arrow

-70%

-0.70
vs -6.96

Q2.22

arrow
arrow

-486%

-4.86
vs -0.70

Q4.22

arrow
arrow

-463%

-4.63
vs -4.86

Q2.23

arrow
arrow

-65%

-0.65
vs -4.63

Q4.23

arrow
arrow

-49%

-0.49
vs -0.65

Institutionnal OwnershipShape

status-up

Earnings Growth

Latest News

ABVX

globenewswire.com

2 hours ago

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
ABVX

globenewswire.com

2 hours ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
ABVX

zacks.com

10 hours ago

Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year?
ABVX

globenewswire.com

16 hours ago

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
ABVX

globenewswire.com

16 hours ago

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease
ABVX

globenewswire.com

16 hours ago

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

New Feature Coming Soon, Stay Tuned!

ShapeShape